Rhumbline Advisers Aquestive Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 140,872 shares of AQST stock, worth $532,496. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140,872
Previous 104,363
34.98%
Holding current value
$532,496
Previous $302,000
54.3%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding AQST
# of Institutions
125Shares Held
47.4MCall Options Held
64.2KPut Options Held
204K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$37.1 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$20.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$16.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$11.3 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.19MShares$8.28 Million0.32% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $202M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...